New pill aims to speed liver healing after cancer surgery
NCT ID NCT06638502
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests an experimental drug called HRX215 in people who had part of their liver removed because colon cancer spread there. The drug is meant to help the liver grow back and work better after surgery. About 80 adults will take either HRX215 or a placebo for 28 days, and researchers will check for side effects and measure liver regrowth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRX215 capsules
What this could lead to
If it works, this could point toward a way to help the liver heal faster after surgery, reducing the risk of liver failure.
What could go wrong
This is a very early (Phase 1/2) trial with only 80 people, so it is not yet known if HRX215 is safe or effective. The drug may cause side effects or show no benefit over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER RESECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Hospitalier Régional Universitaire de Lille (CHRU) Hôpital Claude Huriez
RECRUITINGLille, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cleveland Clinic
NOT_YET_RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Paul-Brousse - Centre Hepato-Biliaire (CHB)
RECRUITINGVillejuif, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact
-
Rabin Medical Center
RECRUITINGPetah Tikva, Israel
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sheba Medical Center
RECRUITINGRamat Gan, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
South Texas Accelerated Research Therapeutics Madrid - CIOCC - Universitario Sanchinarro
NOT_YET_RECRUITINGMadrid, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tel-Aviv Sourasky MC
RECRUITINGTel Aviv, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Univ. Tuebingen - Universitaetsklinik fuer Allgemeine, Viszeral- und Transplantationschirurgie
RECRUITINGTübingen, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••